DXIV - ETF AI Analysis

Top Page

Dimensional International Vector Equity ETF (DXIV)

Rating:62Neutral

Price Target:―

DXIV, the Dimensional International Vector Equity ETF, has a solid overall rating driven by strong positions in high-quality global companies like ASML, Novartis, AstraZeneca, and Kinross Gold, all of which show robust financial performance, positive earnings commentary, and generally supportive technical trends. Energy names like TotalEnergies and Shell also add to the fund’s strength with stable profitability and constructive outlooks. However, weaker holdings such as Bayer and Orange, which face financial and valuation challenges, slightly weigh on the rating, and investors should note the fund’s meaningful exposure to specific large international companies and sectors as a key risk factor.

Positive Factors

Broad International Diversification

The fund spreads its investments across many countries, with meaningful exposure to Japan, the UK, Europe, Canada, and others, which helps reduce reliance on any single market.

Balanced Sector Mix

Holdings are spread across industrials, financials, materials, consumer sectors, energy, technology, and health care, helping to limit the impact of weakness in any one industry.

Solid Recent Performance from Key Holdings

Several of the top positions, including major technology, materials, and health care names, have shown strong gains this year, supporting the ETF’s recent performance.

Negative Factors

Higher Expense Ratio Than Some Broad ETFs

The fund’s fee level is moderate rather than rock-bottom, so cost-conscious investors could find cheaper options in plain-vanilla international index funds.

Small Position Sizes in Top Holdings

Each individual top holding makes up less than a single percent of the portfolio, which can dilute the impact of even strong-performing stocks on overall returns.

Exposure to Lagging Stocks

A few notable holdings, such as some large energy and pharmaceutical names, have shown weak performance this year, which can drag on the fund’s results if the trend continues.

DXIV vs. SPDR S&P 500 ETF (SPY)

AUM146.98M

RegionDeveloped Markets

Expense Ratio0.30%

Beta0.60

IssuerDimensional

Inception DateSep 12, 2024

Dividend Yield2.26%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume7,576

30 Day Avg. Volume11,066

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

78.80

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering2624

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

DXIV Summary

Dimensional International Vector Equity ETF (DXIV) is an international stock fund that invests in companies outside the U.S., without tracking a specific index but following Dimensional’s global equity strategy. It spreads money across many countries like Japan, the UK, and Canada, and across sectors such as industrials, financials, and materials. Well-known holdings include Novartis and ASML. Someone might invest in DXIV to diversify beyond U.S. stocks and seek long-term growth from both developed and emerging markets. A key risk is that international stocks can be volatile and move up or down with global markets and currency swings.

How much will it cost me?The Dimensional International Vector Equity ETF (DXIV) has an expense ratio of 0.3%, which means you’ll pay $3 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it is actively managed, focusing on a refined selection of international stocks to enhance potential returns.

What would affect this ETF?DXIV's focus on developed markets outside the U.S. and its exposure to sectors like Industrials, Financials, and Consumer Cyclical could benefit from global economic growth and increased infrastructure spending. However, challenges such as rising interest rates, geopolitical tensions, or regulatory changes in key regions could negatively impact its performance. The ETF's top holdings in energy and healthcare companies may also be influenced by fluctuating commodity prices and evolving healthcare policies.

DXIV Top 10 Holdings

DXIV leans heavily into non-U.S. industrials, financials, and materials, but its recent story is being written by a few standout names. ASML and Kinross Gold are sprinting ahead, giving the fund a lift with strong momentum in semiconductors and gold. Bayer and BHP are also rising, adding support from healthcare and commodities. On the flip side, TotalEnergies and AstraZeneca are more mixed, occasionally losing steam and acting as mild brakes. Overall, this is a developed-markets ex-U.S. play, with strength coming from a broad international mix rather than any single giant.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
TTE	TotalEnergies SE	0.94%	$1.39M	€139.76B	13.09%	78 Outperform
NVS	Novartis	0.78%	$1.14M	$312.45B	48.76%	80 Outperform
BHP	BHP Group Ltd	0.75%	$1.10M	AU$265.54B	50.41%	68 Neutral
ASML	ASML Holding	0.73%	$1.07M	$559.08B	99.34%	81 Outperform
ROG	Roche Holding AG	0.62%	$917.78K	CHF294.84B	46.01%	73 Outperform
ORA	ORANGE SA	0.61%	$892.93K	€44.88B	62.70%	65 Neutral
BAYN	Bayer	0.60%	$876.24K	€45.00B	99.42%	54 Neutral
AZN	AstraZeneca	0.57%	$844.50K	$323.92B	30.42%	80 Outperform
SHEL	Shell	0.56%	$817.27K	$222.48B	19.61%	78 Outperform
DTE	Deutsche Telekom	0.55%	$807.79K	€158.31B	-5.01%	67 Neutral

DXIV Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

67.48

Positive

100DMA

64.47

Positive

200DMA

61.02

Positive

Market Momentum

MACD

1.35

Negative

RSI

70.22

Negative

STOCH

78.42

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DXIV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 70.41, equal to the 50-day MA of 67.48, and equal to the 200-day MA of 61.02, indicating a bullish trend. The MACD of 1.35 indicates Negative momentum. The RSI at 70.22 is Negative, neither overbought nor oversold. The STOCH value of 78.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DXIV.

DXIV Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
DXIV	―	―	$146.98M	0.30%	62 Neutral
SEIE	―	―	$991.32M	0.50%	63 Neutral
FYLD	―	―	$595.94M	0.59%	61 Neutral
AVSD	―	―	$448.79M	0.23%	65 Neutral
TXUE	―	―	$381.18M	0.65%	65 Neutral
PPIE	―	―	$294.71M	0.49%	69 Neutral

Performance Comparison

DXIV

Dimensional International Vector Equity ETF

72.14

22.26

44.63%

SEIE

SEI Select International Equity ETF

―

FYLD

Cambria Foreign Shareholder Yield ETF

―

AVSD

Avantis Responsible International Equity ETF

―

TXUE

Thornburg International Equity ETF

―

PPIE

Putnam PanAgora ESG International Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents